BioMarin Pharmaceutical Inc. BMRN announced that the FDA has granted the company Investigational New Drug status for its gene therapy candidate, BMN 307 in patients with Phenylketonuria (“PKU”), a rare disease affecting the brain.A successful development of BMN 307, a novel gene therapy for treatment of PKU patients, may help the company to offset any loss of sales due to generic competition for Kuvan and restricted access to Palynziq.